Company Website

Contact Information:
Arron Miller
Phone: 916-677-9075
amiller@castlebiosciences.com

Virtual Exhibit Hall Home
 

TissueCypher Identifies high risk Barrett’s esophagus patients likely to progress to esophageal cancer within five years of endoscopy, including those with NDBE, IND, or LGD histologies.
Optimize management by informing care plan changes up to 55% of the time:

HIGH-RISK* – candidates for eradication therapy

LOW-RISK* – candidates for reduced surveillance

Published Studies